NAGE compared with DFTX: revenue, margins and what each company keeps, and the suppliers and customers both name

NAGENiagen Bioscience, Inc.

Mkt capRevenueRevenue

DFTXDefinium Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

NAGENiagen Bioscience, Inc.

DFTXDefinium Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

NAGE

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±12.6%▼−16.47%×1.31

Q2 FY26±27.5%▼−14.70%×0.53

May 7 '26±14.9%▼−15.69%×1.05

Q1 FY26±22.3%▲+3.24%×0.14

DFTX

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±20.9%0.00%×0.00

May 8 '26±9.7%▼−4.96%×0.52

= impliedNAGE realized, solidDFTX realized, hatchedOne scale, both sides: full bar = 28%× = |realized| ÷ impliedSource: market data

Q1 FY26

±12.9%

▲+0.93%

×0.07

Jan 12 '26—▲+0.29%—

NAGENiagen Bioscience, Inc.

2.07▼−1.90%· post 2.07

Mkt cap$163.9MRevenue$27MQ3 FY26Revenue$129MFY25

DFTXDefinium Therapeutics, Inc.

33.27▲+9.57%· post 33.05

ClosedNov 6 '26

Mkt cap$4.5BRevenue—Revenue—

Compare

ClosedNov 6 '26

NAGENiagen Bioscience, Inc.

DFTXDefinium Therapeutics, Inc.

2.07▼−1.90%post 2.07

Price

33.27▲+9.57%post 33.05

$163.9M

Mkt cap

$4.5B

Q3 FY26$27M

Revenue

—

FY25$129M

Revenue

—

NAGE2.07▼−1.90%vsDFTX33.27▲+9.57%ClosedNov 6 '26